Wenyi Qiu, MS

The prevalence and proportion of spend on high-cost generic drugs is examined.

Annual rates of increase in oncology drug utilization, drug price, and plan spending are quantified and potential contributors are explored.

This article is an early utilization review of newer, more effective, and more costly regimens for the treatment of hepatitis C.

Adherence trends were examined for commercial, Medicaid, Medicare Part D, and self-insured health plans for oral antidiabetic medications, statins, and direct renin inhibitors.